Apricitabine appears to be well tolerated. The most common [[adverse drug reaction|side effect]]s associated with its use were headache (although there was no [[statistical significance|significant]] difference between participants who took apricitabine and those given a [[placebo]]), [[nasal congestion]], and muscle pain.<ref name="pmid16816554">{{cite journal |author=Cahn P |title=Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients |journal=AIDS |volume=20 |issue=9 |pages=1261–8 |date=June 2006 |pmid=16816554 |doi=10.1097/01.aids.0000232233.41877.63 |url= |author2=Cassetti I |author3=Wood R |display-authors=3 |last4=Phanuphak |first4=Praphan |last5=Shiveley |first5=Leeann |last6=Bethell |first6=Richard C |last7=Sawyer |first7=James}}</ref> In a six-month trial, common adverse effects were [[nausea]], [[diarrhea]], [[hypertriglyceridemia|elevated blood levels of triglycerides]], and [[upper respiratory infection]]—similar to those of lamivudine; apricitabine was not associated with abnormal [[lipase]] levels, [[myelosuppression|bone marrow suppression]], or [[hepatotoxicity|liver]] and [[nephrotoxicity|kidney]] toxicity.<ref>{{cite conference |vauthors=Cox S, Moore S, Southby J |title=Safety profile of apricitabine, a novel NRTI, during 24-week dosing in experienced HIV-1 infected patients |booktitle=XVII International AIDS Conference (AIDS 2008) |date=August 5, 2008 |location=Mexico City |url=http://www.aids2008.org/Pag/Abstracts.aspx?SID=256&AID=4376 |id=Abstract TUAB0106 |accessdate=2008-08-29|display-authors=etal}} [http://www.hivandhepatitis.com/2008icr/AIDS2008/docs/082208_c.html Lay summary]</ref> No patients in either study had to stop taking apricitabine because of side effects.

 

